This week Quvium's Jane Ollis was able to share the story of Sonasure and it's development at the launch of a major new fund for health tech start ups in Cornwall. The project led by Creative England and Plymouth University has £600K in grant funds for feasibility studies and development of ideas that fit the challenges areas. For more information to go http://www.creativeengland.co.uk/tech-and-digital/epic
Our CEO Steve will be talking at this year's IDTechEx Show in Santa Clara on November 16th. He will taking about how technology has advanced from fitness trackers. We now have machine learning capabilities, which have ushered a new age of medical wearables that for example can help treat asthma or COPD by monitoring a patient's cough and cough patterns.
Come learn how the combination of microphone technology, machine learning algorithms and real medical science. Steve will also describe how our device's sensors are arrayed and processed, and will discuss other potential applications for sensors in medical products and health trackers, such as breathing detection, crying detection in babies, and fall and impact alerts.
Read more at: https://www.idtechex.com/usa2017/show/en/speakers/10816/machine-learning-medical-wearables-that-can-detect-and-analyze-troubling-coughs
International experts show growing interest in means of monitoring cough, the vital, but little used, bio-marker for disease management and identification.
In late May, Mark Ironmonger, clinical lead for Quvium, attended the
Edwin L. Kendig Jr Pediatric Pulmonary Symposium at the Children’s
Hospital of Richmond at VCU. in Richmond Virginia as a guest of Prof
Bruce Rubin. Professor Rubin holds chairs in Pediatrics and
Biomedical engineering and is highly regarded worldwide for his
innovative work in the field of pediatric pulmonology (or childhood
respiratory disease, depending on from which side of the pond you
originate from). We are fortunate to have him appointed to our
advisory council. There were excellent presentations on many
aspects of respiratory disease from key opinion leads across most
There was a great deal of interest in our means of monitoring cough,
especially as there is little in the way of technology to objectively
assess this vital, but little used, biomarker for disease management
and identification. There is a reliance on subjective questionnaires
and bulky, laboratory-based equipment to gather such data.
Subsequently, Mark was able to engage with professors from South
Africa, Australia, Israel and the US who are interested in exploring
with us the use of our monitor for such conditions as the recognition
and treatment of infections, such as TB and whooping cough, and
naturally, the anticipation of exacerbations of asthma in children at
risk, and pulmonary disease in cystic fibrosis. These professors are,
of course, in addition to the leading academics from London,
including Great Ormond Street, Kings College and Imperial College,
and from Hull, Leeds, Southhampton and Swansea with whom we
are already working.
Thank you to Sarah Faulkner, writer for DrugDeliveryNow and her piece this week following our CEO's, presentation at the recent Medical Sensors Design Conference this month.
Steve (our CEO) talked about Eric Olson, the man who led the development of the 1st drug to treat the underlying causes of cystic fibrosis, and how he'd asked him to look into ways that families could become more engaged with managing a patient’s condition. Olson pointed towards a publication that showed that involving caregivers added 8 years of life expectancy to children with cystic fibrosis.
This has led Steve to the creation of SONASURE of a wearable cough monitor that alerts patients’ care community when a cough is out of the ordinary, so they can intervene before an attack or flare up.
For the full story, please go to:http://www.drugdeliverybusiness.com/quviums-cough-monitor-boosts-compliance-involving-caregivers/
Our CEO Steve Schmidt spoke about the role of SONASURE to help improve the quality of life of patients with a chronic respiratory disease and their care community.
In the US 10M children visited the ER for excessive cough in the last year with 2M children 0-4 have a nebulizer to help manage their condition.
Our device which is proximal, always on and passive, provides text alerts when a significant deviation in cough from baseline is detected, enabling early intervention for these children. This can reduce emotional distress for parents by giving them peace of mind, making it easier for them to share the burden of caring for someone with a chronic disease and reduce the visits to the ER.
Quvium has been recognised as a company that can change the way we live. Compiled by a panel of expert judges, The Futures List features 25 firms transforming the world with their innovative products and services – all based in Kent. Spread across different sectors, what unites all of these companies is a drive for success and ability to transform the future. For more details please go to: http://www.kentonline.co.uk/kent-business/the-future-list/